Clinical features and prognostic analysis in prostate cancer patients under 59 years of age: a report of 72 cases

Abstract

To explore the clinicopathological characteristics and prognostic factors in prostate cancer patients under 59 years of age. From January 2000 to October 2011, 566 prostate cancer patients underwent treatments. Among them, 72 (12.7%) patients under 59 years of age with the integrated clinical data were reviewed. The median follow-up period was 25 months (range: 1 - 108) and the median age 55 years (range: 16 - 59). Four (5.5%) cases had the clinical stage of II, 12 (16.7%) cases of stage III and 56 (77.8%) cases of stage IV. Progression-free survival (PFS), overall survival (OS) and prognostic factors were analyzed. The rate of adenocarcinoma was 86.1% (62/72) and the Gleason score of 8-10 69.1% (29/42). Special type carcinoma accounted for 13.9% (10/72). The median time to androgen-independent prostate cancer (AIPC) was 12 months after endocrine therapy. The 1-, 3- and 5-year PFS were 53.8%, 12.1% and 6.1% and those for OS 85.2%, 58.8% and 15.6% respectively. The prognostic factors were age, baseline prostate special antigen (PSA), types of pathology, tumor stage and local treatment by univariate analysis. The type of pathology was an independent prognostic factor of affecting significantly the prognosis by multivariate analysis. Prostate cancer patients under 59 years of age are characterized by misdiagnosis, complexity of pathology and high malignancy. Comprehensive regiment with predominant local therapy is an effective approach.